Myeloma News and Research

RSS

A promising strategy to overcome drug resistance developed by blood cancer cells

In a collaborative study published in Blood Advances, a research group led by Beate Heissig at Juntendo University and Yousef Salama at An Najah University report a strategy to overcome drug resistance developed by blood cancer cells.

27 Mar 2020

Gero uses AI platform to identify potential anti-COVID-19 drugs

Gero, the leader in AI-driven drug discovery, has used its AI platform to identify the potential anti-COVID-19 drugs. Six of them have been approved, three were withdrawn, and the other nine have been already tested in clinical trials for other indications.

25 Mar 2020

Revolutionary technology could help identify more effective cancer drug combinations

A revolutionary new technology has been applied to reveal the inner workings of individual cancer cells - potentially identifying more effective treatment combinations for people with cancer.

19 Mar 2020

Genetic test could help doctors to identify patients with ultra high risk multiple myeloma

A new genetic test could help doctors pick out patients with the bone marrow cancer multiple myeloma who are at 'ultra high risk' of their cancer progressing aggressively early on.

10 Mar 2020

Isolating Single T-cells of Interest using an Optofluidic Platform

Researchers are in desperate need of single-cell analysis techniques and those that allow the isolation of high-value T-cells for research and development.

From Bruker Cellular Analysis 21 Feb 2020

Single gene cluster loss promotes initiation and progression of multiple myeloma in mice

The loss of one copy of the miR15a/miR16-1 gene cluster promoted initiation and progression of multiple myeloma in mice.

20 Feb 2020

Research reveals novel way to treat cancers using CAR T cell therapy

Too many patients with cancers like multiple myeloma relapse after treatment. This grim reality motivated researchers at Huntsman Cancer Institute at the University of Utah to try to improve the depth and durability of treatment response in multiple myeloma through a new cancer cell targeting mechanism.

10 Feb 2020

CD19 CAR NK cell therapy clinical trial shows encouraging results for hematologic cancers

According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia, with no major toxicities observed.

6 Feb 2020

New discovery could enable scientists to fine-tune activity of cancer-killing immune cells

A discovery by University of North Carolina Lineberger Comprehensive Cancer Center researchers could allow scientists to fine-tune genetically engineered immune cells to heighten their killing power against tumors or to decrease their activity level in the case of severe side effects.

31 Jan 2020

IU researchers receive $3 million NIH grants to study cell functions in the bone marrow

More than $3 million from the National Institutes of Health will allow Indiana University Melvin and Bren Simon Cancer Center researchers to improve understanding of the complex system of how hematopoietic stem cells survive and sustain their function in the bone marrow.

31 Jan 2020

SU2C announces international team for fighting gastric cancer

Stand Up To Cancer announced today that an international team of experts will take a new approach to fighting the world's third-leading cause of cancer death -- stomach (or gastric) cancer.

28 Jan 2020

Daratumumab proves effective in patients with relapsed AL amyloidosis

There's a new treatment option available for patients with AL amyloidosis: daratumumab. Studied in a prospective clinical trial, only one of the two clinical trials of this agent in AL amyloidosis worldwide, researchers have found this anti-cancer drug to be well tolerated and effective in patients with relapsed AL amyloidosis when used with appropriate pre- and post-infusion medications.

27 Jan 2020

The Riney Family Multiple Myeloma Initiative to be established at Dana-Farber

Dana-Farber Cancer Institute will establish the Riney Family Multiple Myeloma Initiative to help improve outcomes and accelerate understanding of the underlying biology for the most challenging types of myelomas, cancers that form in a type of white blood cell called a plasma cell.

13 Jan 2020

Study shows potential new approach to treating two common subtypes of lymphoma

A study at The University of Texas MD Anderson Cancer Center demonstrated a potential new approach to treating two of the most common subtypes of lymphoma through manipulation of molecular programs controlled by the cAMP-response element binding protein.

8 Jan 2020

Temperature fluctuations could give early indications of graft-versus-host disease

By continuously monitoring the body temperature of mice that had undergone bone-marrow transplants, researchers were able to detect early warning signs of graft-versus-host disease - a dangerous, sometimes deadly response of the transplanted immune system - in a simple, non-invasive way.

6 Jan 2020

Recommended amounts of physical activity associated with reduced risk for seven cancers

A pooled analysis of nine prospective studies involving more than 750,000 adults finds that recommended amounts of leisure-time physical activity were linked to a lower risk for seven cancers, with several cancer types having a 'dose/response' relationship.

27 Dec 2019

Researchers discover a way to move precision immunotherapy forward for multiple myeloma

Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way to move precision immunotherapy forward by using genomics to inform immunotherapy for multiple myeloma, a blood cancer, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research, in December.

19 Dec 2019

New combination therapy can lead to durable responses in patients with multiple myeloma

An experimental, off-the-shelf immunotherapy that combines a targeted antibody and chemotherapy can lead to potentially durable responses in multiple myeloma patients whose disease has relapsed or is resistant to other standard therapies.

17 Dec 2019

Risk of specific genetic translocation is higher in patients of African ancestry, shows study

Multiple myeloma is a plasma cell cancer that is more common in patients of African American descent than of European American descent.

10 Dec 2019

Combination therapy is safe and effective for older patients diagnosed with acute lymphoblastic leukemia

A study led by The University of Texas MD Anderson Cancer Center showed that treatment combining lower doses of chemotherapy with the monoclonal antibody inotuzumab ozogamicin (INO), with or without the drug blinatumomab, is safe and effective in patients over 60 years of age who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative ALL.